Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).

Abstract

8046 Background: Pts with NSCLC who are active smokers may have increased erlotinib metabolism v non-smokers, which reduces exposure. Methods: Pts with stage IIIB/IV NSCLC (failed first-line platin...